Tian Zhen, Hu Bei, Miao Min, Zhang Lulu, Wang Lin, Chen Bin
Department of Anesthesiology, Suqian People's Hospital of Nanjing Drum-tower Hospital Group, Suqian, 223800, China.
Department of Anesthesiology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, 223800, China.
BMC Anesthesiol. 2020 Aug 17;20(1):205. doi: 10.1186/s12871-020-01124-5.
To observe the effect of pretreatment with ketorolac tromethamine on sufentanil-induced cough in general anesthesia patients.
A total of 102 patients were screened, and 90 patients were scheduled for elective surgery under general anesthesia. The 90 patients were randomly divided into two groups: the control group (C group) and the observation group (KT group). Five minutes before anesthesia induction, the observation group was given ketorolac tromethamine 0.5 mg/kg intravenously within 3 s, while the control group was given the same amount of normal saline intravenously. All patients were given a sufentanil bolus of 0.5 μg/kg (within 3 s) intravenously. One minute later, propofol 2.5 mg/kg and vecuronium 0.15 mg/kg were injected intravenously, and endotracheal intubation was guided by laryngoscopy. The number of coughs that occurred within 1 min after sufentanil injection was recorded. The mean arterial pressure (MAP), heart rate (HR) and pulse oxygen saturation (SpO) were recorded at T0 (immediately before pretreatment), T1 (5 min after pretreatment), T2 (before intubation), T3 (1 min after intubation) and T4 (5 min after intubation). The incidence of adverse reactions, including nausea and vomiting, dizziness, drowsiness, delay of recovery, restlessness in the recovery period, respiratory depression and postoperative incision pain, was analyzed.
Within 1 min after sufentanil injection, the incidence and severity of cough in the KT group was significantly lower than that in the C group (P < 0.05). At T0, T1, T2, T3 and T4, there were no significant differences in MAP, HR and SpO2 between the two groups (P > 0.05). There was no significant difference in the dosage of sufentanil, propofol, remifentanil and vecuronium, the incidence of nausea and vomiting, the delay of recovery, dizziness, drowsiness or respiratory depression between the two groups (P > 0.05). However, the incidence of restlessness and the number of patients with VAS scores > 3 in the KT group were significantly lower than those in the C group (P < 0.05).
Pretreatment with intravenous ketorolac tromethamine can significantly reduce the incidence of sufentanil-induced cough during induction of general anesthesia, which can also significantly reduce postoperative incision pain and restlessness during the recovery period.
Chinese Clinical Trial Registry (registration number# ChiCTR2000030287 ; date of registration: 27/02/2020).
观察术前使用酮咯酸氨丁三醇预处理对全身麻醉患者舒芬太尼诱发咳嗽的影响。
共筛选102例患者,90例计划行择期全身麻醉手术。将这90例患者随机分为两组:对照组(C组)和观察组(KT组)。麻醉诱导前5分钟,观察组在3秒内静脉注射酮咯酸氨丁三醇0.5mg/kg,而对照组静脉注射等量生理盐水。所有患者均静脉注射0.5μg/kg(3秒内)舒芬太尼推注量。1分钟后,静脉注射丙泊酚2.5mg/kg和维库溴铵0.15mg/kg,并在喉镜引导下行气管插管。记录舒芬太尼注射后1分钟内发生的咳嗽次数。在T0(预处理前即刻)、T1(预处理后5分钟)、T2(插管前)、T3(插管后1分钟)和T4(插管后5分钟)记录平均动脉压(MAP)、心率(HR)和脉搏血氧饱和度(SpO)。分析不良反应的发生率,包括恶心呕吐、头晕、嗜睡、苏醒延迟、苏醒期躁动、呼吸抑制和术后切口疼痛。
舒芬太尼注射后1分钟内,KT组咳嗽的发生率和严重程度显著低于C组(P<0.05)。在T0、T1、T2、T3和T4时,两组间MAP、HR和SpO2无显著差异(P>0.05)。两组间舒芬太尼、丙泊酚、瑞芬太尼和维库溴铵的用量、恶心呕吐的发生率、苏醒延迟、头晕、嗜睡或呼吸抑制无显著差异(P>0.05)。然而,KT组躁动的发生率和视觉模拟评分(VAS)>3分的患者数量显著低于C组(P<0.05)。
静脉注射酮咯酸氨丁三醇预处理可显著降低全身麻醉诱导期间舒芬太尼诱发咳嗽的发生率,还可显著减轻术后切口疼痛和苏醒期躁动。
中国临床试验注册中心(注册号:ChiCTR2000030287;注册日期:2020年2月27日)。